AstraZeneca has become the first company to get approval for the combination of an immunotherapy with a PARP inhibitor for treating endometrial cancer. The European Commission has cleared AZ's PD-L1 ...
Bristol-Myers Squibb has claimed its second FDA approval in the space of a few days for its immuno-oncology combination of Opdivo and Yervoy, this time in newly diagnosed liver cancer. PD-1 inhibitor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback